Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.26789 http://scihub22266oqcxt.onion/10.1002/jmv.26789 33427302!8014628!33427302     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33427302&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2021 ; 93 (4): 2548-2552 Nephropedia Template TP {{tp|p=33427302|t=2021. Antibody response to SARS-CoV-2 in infected patients with different clinical outcome |pdf=|usr=}}{{33427302}} gab.com Text Antibody response to SARS-CoV-2 in infected patients with different clinical outcome JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=33427302 #FOAvip Data regarding antibody responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in patients infected with COVID-19 are not yet available. In this study, we aimed to evaluate serum antibody responses in patients regardless of the outcome. We measured the circulating immunoglobulin G (IgG) antibody levels in 60 subjects with a certified history of SARS-CoV-2 infection by using immunoenzymatic, chemiluminescent, and Neutralization assays. Half patients had a severe infection, the other half were pauci-symptomatic. We analyzed their antibody response to see the trend of the humoral response. Our results showed a significant difference in circulating IgG level among the two groups. The neutralizing antibody response against SARS-CoV-2 was significantly higher among those who had severe disease. Furthermore, ten subjects from each group were screened twice, and a declining antibody trend was observed in pauci-symptomatic individuals. These findings provide evidence that humoral immunity against SARS-CoV-2 in pauci-symptomatic people is weak and may not be long-lasting. This may have implications for immunity strategy and prevention, since it is still not clear whether a time-dependent decrease of both circulating and neutralizing antibodies to nonprotective levels could occur in a longer time span and whether potential vaccines are able to induce a herd immunity and a durable response. Twit Text FOAVip Antibody response to SARS-CoV-2 in infected patients with different clinical outcome ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=33427302 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33427302 #FOAvip English Wikipedia <ref>{{Cite pmid|33427302}}</ref> Antibody response to SARS-CoV-2 in infected patients with different clinical outcome #MMPMID33427302 Anichini G; Gandolfo C; Terrosi C; Fabrizi S; Miceli GB; Gori Savellini G; Prathyumnan S; Franchi F; Cusi MG J Med Virol 2021[Apr]; 93 (4): 2548-2552 PMID33427302show ga Data regarding antibody responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in patients infected with COVID-19 are not yet available. In this study, we aimed to evaluate serum antibody responses in patients regardless of the outcome. We measured the circulating immunoglobulin G (IgG) antibody levels in 60 subjects with a certified history of SARS-CoV-2 infection by using immunoenzymatic, chemiluminescent, and Neutralization assays. Half patients had a severe infection, the other half were pauci-symptomatic. We analyzed their antibody response to see the trend of the humoral response. Our results showed a significant difference in circulating IgG level among the two groups. The neutralizing antibody response against SARS-CoV-2 was significantly higher among those who had severe disease. Furthermore, ten subjects from each group were screened twice, and a declining antibody trend was observed in pauci-symptomatic individuals. These findings provide evidence that humoral immunity against SARS-CoV-2 in pauci-symptomatic people is weak and may not be long-lasting. This may have implications for immunity strategy and prevention, since it is still not clear whether a time-dependent decrease of both circulating and neutralizing antibodies to nonprotective levels could occur in a longer time span and whether potential vaccines are able to induce a herd immunity and a durable response. |Adult[MESH] |Aged[MESH] |Animals[MESH] |Antibodies, Neutralizing/blood[MESH] |Antibodies, Viral/*biosynthesis/*blood[MESH] |Antibody Formation[MESH] |COVID-19/immunology/*virology[MESH] |Chlorocebus aethiops[MESH] |Humans[MESH] |Immunity, Humoral[MESH] |Immunoglobulin G/blood/isolation & purification[MESH] |Middle Aged[MESH] |Neutralization Tests[MESH] |SARS-CoV-2/*immunology[MESH]Antibody response to SARS-CoV-2 in infected patients with different cl(epmc).pdf DeepDyve Pubget Overpricing